Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Status:
Completed
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
To investigate bevacizumab in combination with carboplatin and capecitabine for patients with
unresectable or metastatic GEJ or gastric cancers. We hope that by adding bevacizumab to
standard chemotherapy for this patient population we will improve Progression Free Survival
by 90% over historical controls.